Recruiting · registry status

Testing scans for a protein linked to Parkinson’s

Researchers study imaging substances designed to help detect changes associated with alpha-synuclein, a protein linked to Parkinson’s and related conditions.

Learning by observing or collecting information · Study reference: NCT06949670

Plain-language introduction written with AI from the registry; not independently checked by a clinician. Read the original details below ↓

Open the official registry record ↗

Who can join?

Ages 18 years to 80 years · Also accepts healthy volunteers

These are starting points, not the full rules. The research team can tell you whether the study is right for your situation.

Read all the rules for taking part

Sex eligibility reported by registry: all

Inclusion Criteria: * (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated PD (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled α-Syn PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. Exclusion Criteria: * (i) patients with none PD syndrome; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.

Full study name & original research details

Official study title

Alpha-Synuclein PET/CT in Various α-Syn-Related Disease

Original description

To evaluate the potential usefulness of 18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various α-Syn-related disease patients.

Further description from the registry

Subjects with various α-Syn-related disease patients underwent 18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06 PET/CT either for an initial assessment or for recurrence detection. Lesions uptake was quantified by the maximum standard uptake value (SUVmax). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06 PET/CT were calculated.

Conditions reported: Alpha Synuclein Pathology; Alpha-Synuclein; Parkinson Disease

Study type: Observational
Interventions: 18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06
Phases: Not reported
Sponsor: Tianjin Medical University
Start date reported by registry: 2025-04-01 (actual)

Registry updated: 2026-09-08 · Status last verified by the registry submitter: 2026-09

Registry records retrieved 2026-10-11 (UTC). Individual records may have older updates. Recruitment and eligibility must be confirmed with the study team.

Contact the research team

Public study contacts supplied to the registry. Ask whether recruitment is still open and what participation involves.

Ying Wang, MD · +8618702292537 · macrossplusvoices@163.com

Li Cai, MD · +862260362190 · xcl242004@126.com

Study locations

Site status can differ from overall study status. “Status not reported” means local availability needs confirmation. Remote participation and travel arrangements must be checked with the team.

The First Affiliated Hospital of University of Science and Technology of China

Hefei, Anhui, China

Recruiting

Qiang Xie, PhD · +8613721108043 · ahxq1980@163.com

The Affiliated Hospital of Qingdao University

Qingdao, Shandong, China

Recruiting

Guangjie Yang, MD · +8617853297979 · ygj_2815@qdu.edu.cn

Tianjin Medical University General Hospital

Tianjin, Tianjin Municipality, China

Recruiting

Ying Wang, MD · +8618702292537 · macrossplusvoices@163.com

Ying Wang, MD

The original descriptions and participation rules come from the registry. Participation is voluntary and does not guarantee benefit.